JHP Pharmaceuticals has entered into a multi‐year contract manufacturing agreement with an undisclosed biotechnology company. JHP will be responsible for the manufacture and supply of an approved therapy used to treat cancer. Stuart Hinchen, president and co‐founder of JHP, said, “We recognize that being selected to produce this crucial drug demonstrates our ability to meet critical marketplace needs. JHP was able to achieve the rigorous timelines required to manufacture this drug through a q...